Industry Perspectives

The Industry Perspectives format offers sponsors a platform to present educational content from their company’s point of view in a concise, engaging 8–10-minute video presentation. These presentations are delivered by a key opinion leader or a member of the company’s medical or executive team, providing valuable insights and expertise.

Explore the presentations below to access high-quality content from our industry partners.

Driving Broader Impact: The Emerging Role of Radio-Ligand Therapies

Dr. Ilya Gipp on personalization and AI in radioligand therapy.

From Silos to Synergy: Data-Driven Strategies in Prostate Cancer Care

MRI can enhance integration throughout prostate cancer treatment.

Large-Scale, Prospective, Clinical Validation Study of the Diagnostic Performance of IsoPSA Without and in Combination with Multi-Parametric MRI for the Detection of High Grade Prostate Cancer

IsoPSA validated as a tool for smarter biopsy decisions.

MyProstateScore 2.0 (MPS2): A Novel, Noninvasive Urine Test Prior to Prostate Biopsy

Jeffrey J. Tosoian, MD, MPH, introduces the MyProstateScore 2.0 test as a non-invasive urine-based diagnostic tool for prostate cancer.

Industry Perspective: Cxbladder Triage AUA Microhematuria Guidelines Inclusion

Jay K. Jhaveri, MD, MPH, discusses the key changes in the 2025 AUA microhematuria guidelines and their implications for clinical practice.

UroVation Interview: Envision Sciences – Advancing Cancer Diagnosis and Prognosis

GRU UroVations: Dr. Crawford and Steven Stone, PhD, Envision Sciences, Salt Lake City, Utah, discuss IHC Biomarkers in prostate cancer.

Expert Discussion on LDR Brachytherapy for Prostate Cancer

Drs. Keyes, Kurtzman, and Crawford highlight how LDR brachytherapy improves patient outcomes and collaboration between urologists and radiation oncologists.

Connected Care and Latest Developments in Prostate Cancer Management

Ilya Gipp, MD, PhD, discusses innovative diagnostic and therapeutic approaches in prostate cancer management.

Understanding Metastatic Castration-Resistant Prostate Cancer

Shell Liang, PhD, discusses metastatic castration-resistant prostate cancer (mCRPC), which does not respond to androgen deprivation therapy (ADT).

Emergent Applications of Prostate Cancer Mapping with Artificial Intelligence

Alan Priester, PhD explores the applications of artificial intelligence (AI) in mapping prostate cancer and precision diagnosis and treatment.

Convergent Therapeutics: Next-Generation Targeted Radiotherapies

Philip Kantoff, MD, explores advancements in targeted radiotherapies and their potential to revolutionize prostate cancer treatment.

Diagnostic and Prognostic Biomarkers for Prostate Cancer

Ericka Bagi, BSN, RN, discusses diagnostic and prognostic biomarkers in prostate cancer.